Clinical Development Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

Clinical Development Stocks Recent News

Date Stock Title
Jul 1 ALNY Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
Jun 30 ALNY Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
Jun 29 ALNY Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
Jun 28 ICLR Is Icon PLC (ICLR) a Solid Growth Stock? 3 Reasons to Think "Yes"
Jun 28 REGN What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Jun 28 MEDP Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
Jun 28 REGN Regeneron lymphoma antibody drug endorsed for conditional approval in EU
Jun 28 REGN Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Jun 27 REGN Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Jun 27 ALNY Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Jun 27 ALNY Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Jun 27 SRPT Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Jun 26 REGN Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Jun 26 MEDP Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
Jun 26 SRPT Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Jun 26 SRPT Sarepta cut to Neutral at Citi on risks to valuation
Jun 26 SRPT Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
Jun 25 MEDP 3 Undervalued Stocks With Intrinsic Discounts Ranging From 26.7% To 47.9%
Jun 25 ALNY Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Jun 25 REGN Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Clinical Development

Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

Browse All Tags